Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelavespib in Accelerated or Blast Phase MPN
NCT05612633Phase 2Withdrawn
- Sponsor
- Samus Therapeutics
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of zelavespib in Myeloproliferative Neoplasm (MPN), sponsored by Samus Therapeutics. Primary endpoints: Maximum Tolerated Dose at 6 months and Safety and Tolerability at 6 months. Planned start Jun 2022; status: withdrawn.
02
Drugs
zelavespib
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT05612633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05612633.